![CDX2/UBTF ALL a novel gene expression B-ALL, a high-risk subtype. Top. Gene expression profiling of 302 B-ALL cases shown in a tSNE plot. Bottom left. CDX2/UBTF ALL is defined by the unique and universal association of CDX2 cis-deregulation and UBTF::ATXN7L3 fusion. In normal condition, an enhancer in PAN3 interact with the PAN3 promoter. In CDX2/UBTF ALL cases, the deletion, which includes the PAN3 and FLT3 promoters, causes the interaction of the PAN3 enhancer with the CDX2 promoter, leading to CDX2 deregulation. The grey dashed line corresponds to the deletion. Bottom right. Three-years cumulative incidence of relapse of CDX2/UBTF cases as compared to other B-ALL in GRAALL-2005/2014 trials: 75.0% (95%CI[50.6-93.5]) versus 32.4% (95%CI[28.7-36.5]), specific hazard ratio 2.43, 95%CI[1.32-4.46].](https://pbs.twimg.com/media/FiZrgn_WIAAua2k.png?name=small&format=webp)
ALT CDX2/UBTF ALL a novel gene expression B-ALL, a high-risk subtype. Top. Gene expression profiling of 302 B-ALL cases shown in a tSNE plot. Bottom left. CDX2/UBTF ALL is defined by the unique and universal association of CDX2 cis-deregulation and UBTF::ATXN7L3 fusion. In normal condition, an enhancer in PAN3 interact with the PAN3 promoter. In CDX2/UBTF ALL cases, the deletion, which includes the PAN3 and FLT3 promoters, causes the interaction of the PAN3 enhancer with the CDX2 promoter, leading to CDX2 deregulation. The grey dashed line corresponds to the deletion. Bottom right. Three-years cumulative incidence of relapse of CDX2/UBTF cases as compared to other B-ALL in GRAALL-2005/2014 trials: 75.0% (95%CI[50.6-93.5]) versus 32.4% (95%CI[28.7-36.5]), specific hazard ratio 2.43, 95%CI[1.32-4.46].



































